Abstract:Acute myeloid leukemia (AML)—the most frequent form of adult blood cancer—is characterized by heterogeneous mechanisms and disease progression. Developing an effective therapeutic strategy that targets metabolic homeostasis and energy production in immature leukemic cells (blasts) is essential for overcoming relapse and improving the prognosis of AML patients with different subtypes. With respect to metabolic regulation, fructose-1,6-bisphosphatase 1 (FBP1) is a gluconeogenic enzyme that is vital to carbohydrate metabolism, since gluconeogenesis is the central pathway for the production of important metabolites and energy necessary to maintain normal cellular activities. Beyond its catalytic activity, FBP1 inhibits aerobic glycolysis—known as the “Warburg effect”—in cancer cells. Importantly, while downregulation of FBP1 is associated with carcinogenesis in major human organs, restoration of FBP1 in cancer cells promotes apoptosis and prevents disease progression in solid tumors. Recently, our large-scale sequencing analyses revealed FBP1 as a novel inducible therapeutic target among 17,757 vitamin-D-responsive genes in MV4-11 or MOLM-14 blasts in vitro, both of which were derived from AML patients with FLT3 mutations. To investigate FBP1′s anti-leukemic function in this study, we generated a new AML cell line through lentiviral overexpression of an FBP1 transgene in vitro (named FBP1-MV4-11). Results showed that FBP1-MV4-11 blasts are more prone to apoptosis than MV4-11 blasts. Mechanistically, FBP1-MV4-11 blasts have significantly increased gene and protein expression of P53, as confirmed by the P53 promoter assay in vitro. However, enhanced cell death and reduced proliferation of FBP1-MV4-11 blasts could be reversed by supplementation with post-glycolytic metabolites in vitro. Additionally, FBP1-MV4-11 blasts were found to have impaired mitochondrial homeostasis through reduced cytochrome c oxidase subunit 2 (COX2 or MT-CO2) and upregulated PTEN-induced kinase (PINK1) expressions. In summary, this is the first in vitro evidence that FBP1-altered carbohydrate metabolism and FBP1-activated P53 can initiate leukemic death by activating mitochondrial reprogramming in AML blasts, supporting the clinical potential of FBP1-based therapies for AML-like cancers.

Repurposing FBP1: dephosphorylating IκBα to suppress NFκB

Repurposing FBP1: dephosphorylating IB to suppress NFB

Fructose-1,6-bisphosphatase 1 Dephosphorylates IκBα and Suppresses Colorectal Tumorigenesis

Fructose-1,6-bisphosphatase 1 functions as a protein phosphatase to dephosphorylate histone H3 and suppresses PPARα-regulated gene transcription and tumour growth

Fructose-1,6-bisphosphatase Loss Modulates STAT3-dependent Expression of PD-L1 and Cancer Immunity.

A Noncanonical Role of Fructose-1, 6-Bisphosphatase 1 Is Essential for Inhibition of Notch1 in Breast Cancer

Overexpression of FBP1 Enhances Dendritic Cell Activation and Maturation by Inhibiting Glycolysis and Promoting the Secretion of IL33 in Lung Adenocarcinoma

FBP1 orchestrates keratinocyte proliferation/differentiation and suppresses psoriasis through metabolic control of histone acetylation

Dysfunction of Natural Killer Cells by FBP1-induced Inhibition of Glycolysis During Lung Cancer Progression

Down-regulation of FBP1 in Lung Adenocarcinoma Cells Promotes Proliferation and Invasion Through SLUG Mediated Epithelial Mesenchymal Transformation

Fructose-1,6-bisphosphatase 1 suppresses PPARα-mediated gene transcription and non-small-cell lung cancer progression.

Fructose-1,6-bisphosphatase 1 dephosphorylates and inhibits TERT for tumor suppression

Fructose 1,6-bisphosphate inhibits osteoclastogenesis by attenuating RANKL-induced NF-κB/NFATc-1

O-GlcNAcylation of FBP1 Promotes Pancreatic Cancer Progression by Facilitating Its Lys48-linked Polyubiquitination in Hypoxic Environments

Repression of latent NF-κB enhancers by PDX1 regulates β cell functional heterogeneity

Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression

Thermal proteome profiling reveals fructose-1,6-bisphosphate as a phosphate donor to activate phosphoglycerate mutase 1

FBP1 inhibits NSCLC stemness by promoting ubiquitination of Notch1 intracellular domain and accelerating degradation

FBP1-Altered Carbohydrate Metabolism Reduces Leukemic Viability Through Activating P53 and Modulating the Mitochondrial Quality Control System in Vitro

AB180. the Relationship Between Fructose-1, 6-Bisphosphatase and Hypoxia Related Genes Expression in Clear Cell Renal Cell Carcinoma

Loss of FBP1 facilitates aggressive features of hepatocellular carcinoma cells through the Warburg effect.